124 related articles for article (PubMed ID: 24945422)
1. Long-term outcomes of pediatric Graves' disease.
Jevalikar G; Solis J; Zacharin M
J Pediatr Endocrinol Metab; 2014 Nov; 27(11-12):1131-6. PubMed ID: 24945422
[TBL] [Abstract][Full Text] [Related]
2. [Long-term follow up after antithyroid drug treatment in Graves' disease].
Wille T; Müller B; Noth D; Bürgi U; Diem P
Praxis (Bern 1994); 2006 Jul; 95(29-30):1121-7. PubMed ID: 16916174
[TBL] [Abstract][Full Text] [Related]
3. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
[TBL] [Abstract][Full Text] [Related]
4. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.
Tun NN; Beckett G; Zammitt NN; Strachan MW; Seckl JR; Gibb FW
Thyroid; 2016 Aug; 26(8):1004-9. PubMed ID: 27266892
[TBL] [Abstract][Full Text] [Related]
5. Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution.
Ohye H; Minagawa A; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Suzuki M; Yoshihara A; Ito K; Ito K
Thyroid; 2014 Feb; 24(2):200-7. PubMed ID: 23926918
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves' disease: a 120 months prospective study.
Cappelli C; Gandossi E; Castellano M; Pizzocaro C; Agosti B; Delbarba A; Pirola I; De Martino E; Rosei EA
Endocr J; 2007 Dec; 54(5):713-20. PubMed ID: 17675761
[TBL] [Abstract][Full Text] [Related]
7. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study.
Léger J; Gelwane G; Kaguelidou F; Benmerad M; Alberti C;
J Clin Endocrinol Metab; 2012 Jan; 97(1):110-9. PubMed ID: 22031519
[TBL] [Abstract][Full Text] [Related]
8. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
[TBL] [Abstract][Full Text] [Related]
9. The Second Antithyroid Drug Treatment Is Effective in Relapsed Graves' Disease Patients: A Median 11-Year Follow-Up Study.
Kim YA; Cho SW; Choi HS; Moon S; Moon JH; Kim KW; Park DJ; Yi KH; Park YJ; Cho BY
Thyroid; 2017 Apr; 27(4):491-496. PubMed ID: 28001121
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
Massart C; Gibassier J; d'Herbomez M
Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic factors in the relapse of Graves disease].
Miao J; Zhao YJ; Wang S; Jiang XH; Zhao ZF; Gu LQ; Gu XJ; Ning G
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):185-8. PubMed ID: 18785498
[TBL] [Abstract][Full Text] [Related]
12. Remission of Graves' hyperthyroidism treated with methimazole.
Bolaños F; González-Ortiz M; Durón H; Sánchez C
Rev Invest Clin; 2002; 54(4):307-10. PubMed ID: 12415954
[TBL] [Abstract][Full Text] [Related]
13. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
Rink T; Holle LH; Schroth HJ; Garth H
Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
[TBL] [Abstract][Full Text] [Related]
14. Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs.
Quadbeck B; Roggenbuck U; Janssen OE; Hahn S; Mann K; Hoermann R;
Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):406-11. PubMed ID: 17039420
[TBL] [Abstract][Full Text] [Related]
15. Graves disease in children: thyroid-stimulating hormone receptor antibodies as remission markers.
Gastaldi R; Poggi E; Mussa A; Weber G; Vigone MC; Salerno M; Delvecchio M; Peroni E; Pistorio A; Corrias A
J Pediatr; 2014 May; 164(5):1189-1194.e1. PubMed ID: 24518168
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of long-term follow-up and methimazole therapy outcomes of pediatric Graves' disease: a single-center experience.
Bayramoğlu E; Elmaogulları S; Sagsak E; Aycan Z
J Pediatr Endocrinol Metab; 2019 Apr; 32(4):341-346. PubMed ID: 30862763
[TBL] [Abstract][Full Text] [Related]
17. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
[TBL] [Abstract][Full Text] [Related]
18. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Graves' disease in children: The Portuguese experience.
Marques O; Antunes A; Oliveira MJ
Endocrinol Diabetes Nutr (Engl Ed); 2018 Mar; 65(3):143-149. PubMed ID: 29325833
[TBL] [Abstract][Full Text] [Related]
20. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
Liu C; Duan Y; Wu X
Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
